Kyverna Therapeutics, Inc. Finance Lease, Interest Payment on Liability
Kyverna Therapeutics, Inc. (KYTX) reported Finance Lease, Interest Payment on Liability of $51.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FinanceLeaseInterestPaymentOnLiability · last filed 2026-05-12
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for the quarter ending 2026-03-31 was $51.00K, a 34.21% increase year-over-year.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for the quarter ending 2025-03-31 was $38.00K, a 13.64% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for the quarter ending 2024-12-31 was $27.00K, a 42.55% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for the quarter ending 2024-09-30 was $33.00K, a 32.65% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for fiscal 2025 was $417.00K, a 193.66% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for fiscal 2024 was $142.00K, a 24.06% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. finance lease, interest payment on liability for fiscal 2023 was $187.00K.
| Period end | Finance Lease, Interest Payment on Liability 3 month | Finance Lease, Interest Payment on Liability 6 month | Finance Lease, Interest Payment on Liability 9 month | Finance Lease, Interest Payment on Liability 12 month |
|---|---|---|---|---|
| 2026-03-31 | $51.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $417.00K 10-K · filed 2026-03-26 | |||
| 2025-03-31 | $38.00K 10-Q · filed 2026-05-12 | $65.00K derived: sum of 2 quarters · filed 2026-05-12 | $98.00K derived: sum of 3 quarters · filed 2026-05-12 | $138.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $60.00K derived: sum of 2 quarters · filed 2026-03-26 | $100.00K derived: sum of 3 quarters · filed 2026-03-26 | $142.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $33.00K 10-Q · filed 2024-11-13 | $73.00K derived: sum of 2 quarters · filed 2024-11-13 | $115.00K 10-Q · filed 2024-11-13 | $164.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-06-30 | $40.00K 10-Q · filed 2024-08-12 | $82.00K 10-Q · filed 2024-08-12 | $131.00K derived: sum of 3 quarters · filed 2025-03-27 | $180.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-03-31 | $44.00K 10-Q · filed 2024-05-14 | $91.00K derived: sum of 2 quarters · filed 2025-03-27 | $140.00K derived: sum of 3 quarters · filed 2025-03-27 | $187.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $96.00K derived: sum of 2 quarters · filed 2025-03-27 | $143.00K derived: sum of 3 quarters · filed 2025-03-27 | $187.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $49.00K 10-Q · filed 2024-11-13 | $96.00K derived: sum of 2 quarters · filed 2024-11-13 | $140.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $47.00K 10-Q · filed 2024-08-12 | $90.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $44.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |